Park Place Capital Corp Increases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Park Place Capital Corp grew its stake in Kenvue Inc. (NYSE:KVUE) by 18.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,656 shares of the company’s stock after purchasing an additional 2,585 shares during the period. Park Place Capital Corp’s holdings in Kenvue were worth $357,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Planned Solutions Inc. acquired a new position in Kenvue during the 4th quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue in the fourth quarter valued at approximately $28,000. Mather Group LLC. acquired a new position in Kenvue during the first quarter worth $28,000. CVA Family Office LLC purchased a new stake in shares of Kenvue during the 4th quarter worth $32,000. Finally, Pinnacle Bancorp Inc. lifted its stake in shares of Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after purchasing an additional 526 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $17.95 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue Inc. has a 1-year low of $17.75 and a 1-year high of $26.60. The company has a 50-day moving average of $19.16 and a 200-day moving average of $19.95. The company has a market capitalization of $34.37 billion, a P/E ratio of 23.01, a PEG ratio of 1.93 and a beta of 1.41.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. The company’s quarterly revenue was down 24.9% on a year-over-year basis. Equities analysts expect that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were given a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.46%. Kenvue’s payout ratio is currently 102.56%.

Analyst Ratings Changes

Several research firms recently weighed in on KVUE. William Blair initiated coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective on the stock. HSBC raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $21.00 price target on shares of Kenvue in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.09.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.